MDR Klebsiella: Causes, Infections, and Treatment Options

Multidrug-resistant (MDR) Klebsiella pneumoniae is a hospital-acquired bacterium that has learned to shrug off three or more classes of antibiotics, making infections it causes extraordinarily difficult to treat. A global meta-analysis estimated the pooled prevalence of nosocomial MDR K. pneumoniae at about 33%, meaning roughly one in three hospital-linked Klebsiella isolates now resists multiple drug families.¹ The bacterium sits on the World Health Organization’s critical-priority pathogen list, and the strains circulating today carry resistance tricks that did not exist a generation ago. Understanding how these strains arise, what infections they cause, and which treatments still work is useful not just for clinicians but for anyone who might find themselves or a family member in an ICU bed.

Why Klebsiella Becomes Multidrug-Resistant

K. pneumoniae picks up resistance in two main ways. The first is through enzymes that destroy antibiotics before they can work. Extended-spectrum beta-lactamases, or ESBLs, chew through penicillins and most cephalosporins. Among the most widely detected ESBL gene in clinical K. pneumoniae isolates worldwide is blaCTX-M-15, often found alongside other beta-lactamase genes on the same mobile genetic element.² When ESBL-producing strains are hammered with carbapenems (the “last-resort” beta-lactams), a second tier of enzymes can emerge. The three carbapenemase families that matter most globally are KPC, NDM, and OXA-48-like enzymes, each with different geographic strongholds and different drug-resistance profiles.³

The second pathway is structural change. Bacteria can lose or alter porins, the channels in their outer membrane that let antibiotics in, or ramp up efflux pumps that actively push drugs back out. These changes often layer on top of enzyme production, so a single isolate may carry an ESBL, a carbapenemase, and a leaky outer membrane all at once. When this happens, the list of antibiotics that still work gets very short.

What makes the situation especially alarming is that many of these resistance genes travel on plasmids, small loops of DNA that bacteria swap with each other like trading cards. Whole-genome studies have found plasmids that carry both resistance genes and virulence genes simultaneously. In one Chinese investigation, researchers identified a single plasmid harboring a carbapenemase gene (blaKPC-2), an ESBL gene, and hypervirulence genes that help the bacterium evade the immune system.⁴ A bacterium carrying that kind of genetic cargo is simultaneously harder to kill and better at causing severe disease.

The Carbapenem-Resistant Problem Within MDR

Not all MDR Klebsiella is carbapenem-resistant, but the carbapenem-resistant subset (often called CRKP) is the one that generates the most clinical dread. A large systematic review across 14 countries estimated the overall prevalence of carbapenem-resistant K. pneumoniae among hospital-acquired infections at about 29%.⁵ In settings where carbapenems are heavily used, such as ICUs in parts of East Asia, the Middle East, and southern Europe, rates can climb higher.

What makes CRKP especially dangerous is how few conventional antibiotics it leaves on the table. In one study of K. pneumoniae isolates from ventilator-associated pneumonia patients, resistance rates exceeded 80% for cephalosporins, aminoglycosides, and fluoroquinolones, with carbapenem resistance around 70%.⁶ A handful of strains have even developed resistance to colistin, historically the drug of last resort. That resistance typically arises through mutations in the chromosomal gene mgrB, which disrupts the bacterium’s outer membrane lipid regulation and blocks colistin from binding effectively.⁷ When both carbapenem resistance and colistin resistance appear in the same isolate, clinicians are left with almost nothing in the medicine cabinet.

Where These Infections Happen and Who Is at Risk

MDR K. pneumoniae is overwhelmingly a hospital pathogen. It thrives in ICUs, surgical wards, and long-term care facilities, environments where patients have weakened immune defenses and frequent exposure to antibiotics and invasive devices. The most common infections are pneumonia (especially ventilator-associated), bloodstream infections, urinary tract infections linked to catheters, and surgical site infections.

Several patient-level risk factors consistently emerge across studies. A five-year retrospective cohort in Shanghai identified genitourinary disease, invasive ventilation, any antibiotic use in the previous 90 days, and prior carbapenem use as independent predictors of MDR K. pneumoniae bloodstream infection.⁸ A Saudi Arabian study found that being male, being 65 or older, having diabetes, having chronic obstructive pulmonary disease, or being admitted to an ICU all increased the odds of acquiring an MDR K. pneumoniae infection.⁹ A multicenter Lebanese study added recent cancer chemotherapy to the list of significant predictors.¹⁰

In short, prior antibiotic exposure is the most modifiable risk factor. The more antibiotics a patient has recently received, the greater the selective pressure favoring resistant strains. Devices that breach the body’s natural barriers, like ventilators, central venous catheters, and urinary catheters, provide a direct entry point. And chronic diseases that impair the immune response (diabetes, COPD, blood cancers) make it harder for the body to clear even a small inoculum.

How Klebsiella Spreads in Hospitals

Person-to-person spread typically happens through contaminated hands of healthcare workers, but the bacterium also lives in the environment. An investigation of a persistent CRKP outbreak in a surgical ICU traced the epidemic strain to sink traps, and the outbreak only resolved after the sink traps were physically replaced.¹¹ Biofilms that K. pneumoniae forms on surfaces and medical devices also play a role; these slimy communities protect bacteria from both cleaning agents and antibiotics.¹²

There is also a silent reservoir: the human gut. Epidemiological data suggest that asymptomatic gastrointestinal carriage serves as a launching pad for infections in the same patient and allows host-to-host spread via the fecal-oral route.¹³ A patient can carry a resistant strain in the gut for weeks without symptoms, then develop an invasive infection if their immune defenses drop or a device breaches their intestinal barrier. This is why some hospitals now screen ICU admissions with rectal swabs, looking for colonized patients before an infection ever develops.¹⁴

Outside the hospital, wastewater systems have been flagged as a potential pathway for resistant K. pneumoniae strains to enter the broader environment. One genomic study traced isolates from hospital sewage through a wastewater treatment plant and into the surrounding environment.¹⁵ However, the practical significance of environmental reservoirs for human infections remains debated. A study in India found limited overlap between K. pneumoniae clones in animals, the environment, and humans, suggesting that in at least some settings, hospital-to-hospital and patient-to-patient transmission drives most of the problem.¹⁶

Clinical Consequences and Mortality

MDR K. pneumoniae infections carry substantially worse outcomes than their drug-susceptible counterparts. For bloodstream infections, one analysis found the risk of death from CRKP was about three times higher than from carbapenem-susceptible K. pneumoniae.¹⁷ Independent predictors of death include septic shock at presentation, inadequate initial antibiotic therapy, and prior corticosteroid use.¹⁸ Hematological cancers also strongly predict death in K. pneumoniae bloodstream infections, likely because these patients have profoundly impaired immune defenses.¹⁹

Ventilator-associated pneumonia caused by MDR Klebsiella is especially lethal when other bacteria are present at the same time. In a study of 86 such episodes, cases where additional pathogens were co-infecting had a 60-day mortality of 50%, compared with about 28% when MDR Klebsiella was the only organism.²⁰ This gap persisted even when clinicians chose antibiotics that lab tests confirmed should work, suggesting that multi-organism infections create a biologically more hostile environment that antibiotics alone cannot easily resolve.

Antibiotic Treatment Options

What you can use against MDR K. pneumoniae depends entirely on which resistance genes the strain carries. The treatment landscape has shifted dramatically in the last decade, largely because of newer beta-lactam/beta-lactamase inhibitor combinations that were designed specifically for resistant gram-negative bacteria.

For KPC-producing strains (the most common carbapenemase type in the Americas and parts of Europe and Asia), three combinations have shown clear improvements over the older approach of colistin-based regimens: ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-cilastatin-relebactam.²¹ Among these, ceftazidime-avibactam has the broadest track record, and a cost-utility analysis found it was associated with lower mortality and fewer hospital days compared to colistin-meropenem, at a modest additional cost per patient.²²

NDM-producing strains are a harder problem, because NDM is a metallo-beta-lactamase that none of the currently approved beta-lactamase inhibitors can neutralize on their own. The preferred strategy for NDM-producing infections is either ceftazidime-avibactam combined with aztreonam, or cefiderocol as monotherapy.²³ Cefiderocol is a siderophore cephalosporin, meaning it hijacks the bacterium’s own iron-transport channels to sneak inside. Post hoc analysis of two randomized trials showed a clinical cure rate of about 72% and a microbiological eradication rate of about 78% in patients with infections caused by metallo-beta-lactamase-producing bacteria that tested susceptible to cefiderocol, though 28-day mortality in that subgroup was still about 22%.²⁴ Susceptibility testing matters enormously here: cefiderocol does not automatically work against all NDM producers, and real-time emergence of heteroresistance within the same patient has been documented.²⁵

A few additional agents deserve mention. Plazomicin, a next-generation aminoglycoside, works well against KPC producers but is less reliable against NDM strains because those organisms frequently co-carry enzymes that modify the bacterial ribosome in a way that blocks aminoglycosides. Eravacycline, a newer tetracycline, achieved about 84% susceptibility against CRKP isolates in one in-vitro study and showed synergy with polymyxin B in some resistant strains, though clinical data for this drug against CRKP remain thin.²⁶ Colistin-based regimens, once the default for pan-resistant infections, are now generally considered inferior to the newer agents both in survival and side-effect profile.²⁷

Detecting Resistance Quickly

Choosing the right antibiotic hinges on knowing which resistance genes a strain carries, and traditional culture methods can take two to three days. That delay matters when every hour of inappropriate therapy raises the odds of death. Rapid diagnostic tools are closing the gap.

The NG-Test CARBA 5, an immunochromatographic assay (essentially a lateral-flow strip, similar in concept to a COVID rapid test), can identify the five most common carbapenemase families directly from bacterial colonies in about 15 minutes. In a recent evaluation, it achieved about 99% sensitivity and 100% specificity overall.²⁸ Molecular approaches like LAMP (loop-mediated isothermal amplification) can detect specific resistance genes with high accuracy and do not require the expensive thermocyclers used in standard PCR, making them more practical for resource-limited labs.²⁹ Flow cytometry-based methods are also being explored and show high sensitivity for detecting KPC and NDM genes, though specificity for some classes still needs improvement.³⁰

Phage Therapy and Vaccines on the Horizon

Because antibiotic options keep narrowing, researchers are looking beyond traditional drugs. Bacteriophages, viruses that infect and kill bacteria, are among the most actively pursued alternatives. Phage therapy for K. pneumoniae has been tested in cocktails, in combination with antibiotics, and using purified phage-derived proteins like endolysins that punch holes in the bacterial cell wall.³¹

A comparative pilot study of inhaled phage therapy for ventilator-associated pneumonia found encouraging results. By day 14, targeted phage therapy cleared K. pneumoniae from respiratory samples in six of seven patients, compared with four of seven receiving antibiotics alone. Patients in the phage group also showed improved oxygenation, earlier weaning from the ventilator, and earlier discontinuation of antibiotics, with no treatment-related adverse events.³² The sample sizes are still small, and regulatory frameworks for phage therapy remain underdeveloped in most countries, but the direction of the evidence is promising.

Vaccines against K. pneumoniae have been elusive, partly because the bacterium’s capsule comes in dozens of serotypes, making a one-size-fits-all vaccine difficult. A tetravalent bioconjugate vaccine called Kleb4V, targeting four O-antigen serotypes that together are estimated to cover about 70% of K. pneumoniae strains causing human infections worldwide, recently completed a first-in-human phase I trial. The vaccine triggered strong antibody responses across all four serotypes in adults aged 55 to 70, with statistically significant increases over placebo.³³ Whether those antibodies translate into protection against actual infections is the question phase II and III trials will need to answer.

The Financial Toll

Beyond the clinical impact, MDR and carbapenem-resistant K. pneumoniae infections impose a staggering economic burden. Patients with CRKP bloodstream infections or pneumonia incur roughly double the hospital costs of patients with susceptible strains. One matched analysis found median total hospitalization costs of about $23,000 for CRKP patients versus about $12,000 for susceptible cases, with the excess costs driven primarily by non-antibiotic medications and supportive therapies rather than by the antibiotics themselves.³⁴

At a population level, a 2019 analysis from China estimated that about 263,000 hospital inpatients had CRKP infections that year, resulting in direct medical costs of $0.61 billion and indirect costs (lost productivity, disability) of $3.85 billion, for a total economic impact of roughly $4.5 billion.³⁵ Those numbers reflect a single country and a single year. The global figure is inevitably much larger, though comprehensive multinational estimates are still lacking.

Catheter-Associated Urinary Tract Infections

While bloodstream infections and pneumonia dominate the headlines, catheter-associated urinary tract infections caused by K. pneumoniae deserve attention because they are common, often overlooked, and serve as a persistent reservoir for resistant strains. In one hospital cohort, over 60% of patients with K. pneumoniae catheter-associated UTIs had ESBL-producing or MDR isolates, and the majority had been hospitalized for longer than a month.³⁶ These infections often respond poorly to standard antibiotic regimens, and the biofilm that K. pneumoniae forms on catheter surfaces makes eradication even harder.

An intriguing case report explored using intermittent catheterization, which physically disrupts the biofilm by removing the catheter at regular intervals, combined with pelvic floor rehabilitation to restore the patient’s ability to urinate independently. Once the catheter was no longer needed, the source of reinfection was eliminated.³⁷ This is a single case and far from established practice, but it highlights a broader principle: when dealing with device-associated MDR infections, removing the device is sometimes more effective than adding another antibiotic.

Strains That Carry Both Resistance and Hypervirulence

Classic K. pneumoniae strains that cause hospital infections tend to be drug-resistant but not especially virulent on their own; they exploit weakened patients. A separate lineage, called hypervirulent K. pneumoniae (hvKp), is known for causing aggressive community-acquired infections like liver abscesses in otherwise healthy people, but those strains were historically drug-susceptible. The nightmare scenario is the convergence of both traits in one organism, and that convergence is already happening.

Genomic studies have identified strains, particularly those belonging to the high-risk sequence type ST11, that carry plasmids encoding both carbapenem resistance and hypervirulence factors like aerobactin (an iron-scavenging system) and hypermucoviscosity regulators.³ Some of these convergent strains even co-produce KPC-2 and NDM-5, meaning they resist both traditional carbapenems and many of the newer beta-lactamase inhibitor combinations. Isolates like these have been found co-harboring more than ten resistance elements alongside virulence plasmids.³⁸ These dual-threat strains are still relatively uncommon, but their very existence underscores how rapidly K. pneumoniae can accumulate dangerous genetic cargo through plasmid exchange.